

TECH CENTER 1600/2900





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Jonathan S. Stamler, Joseph Bonaventura, John R. Pawloski

and Timothy J. McMahon

Application No.:

10/045,603

Group Art Unit:

1651

Filed:

October 23, 2001

Examiner:

Unknown

Confirmation No.:

1

3692

Title:

Red Blood Cells Loaded Sith S-Nitrosothiol and Uses Therefor

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope
addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington,
on 11/8/02 Wendy Morrissey Rate Signature
Wendy Morrissey
Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

Sir:	
This I	nformation Disclosure Statement is submitted:
[]	under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either:
	[] a Statement under 37 CFR 1.97(e), as checked below, or
	[] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with:
	[] a Statement under 37 CFR 1.97(e), as checked below, and

[] under 37 CFR 1.97(i):

a \$180.00 fee under 37 CFR 1.17(p), or

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

Statem	ient Un	der 3/ CFR 1.9/(e)							
[]	any co	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or							
[]	comm knowl in the	m of information contained in this Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart foreign application, and, to the edge of the undersigned, after making reasonable inquiry, no item of information contained information disclosure statement was known to any individual designated in 37 CFR more than three months prior to the filing of this Information Disclosure Statement.							
Statem	ent Un	der 37 CFR 1.704(d) (Patent Term Adjustment)							
_		Applies to original applications (other than design) filed on or after May 29, 2000							
[]	commi was no	tem of information contained in the Information Disclosure Statement was cited in a unication from a foreign patent office in a counterpart application and this communication traceived by any individual designated in § 1.56(c) more than thirty days prior to the of the Information Disclosure Statement.							
[X]	Enclos	sed herewith is form PTO-1449:							
	[]	Copies of the cited references are enclosed.							
-	[X]	Copies of cited references AI, AQ2, AY3, AZ3 and AR4 are enclosed. Other cited references were entered in prior applications, U.S. Application No. 09/724,305, U.S. Application No. 08/873,679 and U.S. Application No. 08/616,255, to which priority under 35 U.S.C. 120 is claimed. The earlier application files contain copies of the cited references which are not enclosed with this paper.							
	[]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.							
	[]	The "concise explanation" requirement (non-English references) for reference(s) [under 37 CFR 1.98(a)(3) is satisfied by:							
		[] the explanation provided on the attached sheet.							
		[] the explanation provided in the Specification.							
		[] submission of the enclosed International Search Report.							
		[] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.							
		[] the enclosed English language abstract.							
£323	A 1.								
[X]	Applic	ant requests that the following pending applications be considered:							
Examiner's Initials									
		U.S. Patent Application No. 08/616,371, by Jonathan S. Stamler, filed March 15, 1996 (not published)							
		U.S. Patent Application No. 08/796,164, by Jonathan S. Stamler and Andrew J. Gow, filed February 6, 1997 (not published)							

	-	U.S. Patent Application No. 08/874,992, by Jonathan S. Stamler and Andrew J. Gow, filed June 12, 1997 (not published)
· · · · · · · · · · · · · · · · · · ·	-	U.S. Patent Application No. 09/369,966, by Jonathan S. Stamler and Andrew J. Gow, originally filed August 6, 1999 (CPA filed October 30, 2001 and published as Publication No. 20020037839 on March 28, 2002)
-	-	U.S. Patent Application No. 10/066,320, by Jonathan S. Stamler, Andrew J. Gow and David J. Singel, filed January 31, 2002 (not published)
		Examiner Date
	[]	A copy of each above-cited application, including the current claims, is enclosed.
	[X]	A copy of each above-cited application, including the current claims, is enclosed, except for 08/616,371 and 08/796,164, which were entered in the parent application, U.S. Application No. 09/724,305, to which priority under 35 U.S.C. 120 is claimed.
		is requested to return a copy of the above list of pending applications, indicating which re considered, with the next office communication.
It is re	quested	that the information disclosed herein be made of record in this application.
Metho	d of pay	ment:
[]		ck for the fee noted above is enclosed, or the fee has been included in the check with the panying Reply. A copy of this Statement is enclosed.
]	Please enclose	charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is ed.
[X]	Please	charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.
		Respectfully submitted,
		HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
		By <u>Carol G. Egner</u> Carol A. Egner Registration No. 38,866 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, Massachusetts 01742-9133

Dated: November 8, 2002

OIPE				ATTORNEY DOCKET NO. 1818.1009-009	APPLICAT		옷	Z	
I TN AN APPILICATION			APPLICANT Jonathan S. Stamler, et al.			CH CENTER	NOV 1		
101 1 4	October 29, 2002 (Use several sheets if necessary)			FILING DATE October 23, 2001	confirmate 3692	TION NO.	GROWN 200		
CRADENA SE			PATENT DOCUMENTS	<u> </u>		2900	_ 		
EXAM- INER INI- TIAL	INER INI- DOCUMENT NUMBER			ISSUE DATE / PUBLICATION DATE	NAME				
	AA	5,380,758		01/10/95	Stamle	r, et a	1.		
	AB	5,405,919		04/11/95	Keefer, et al.				
	AC	4,900,719		02/13/90	Means,	et al.			
	AD	5,593,876		01/14/97	Stamle	r, et a	al.		
	AE	5,480,866		01/02/96	Bonave	ntura,	et al		
	AF	5,427,797	·	06/27/95	Frostell, et al.				
	AG	5,574,068		11/12/96	Stamler, et al.				
	НА	6,197,745		03/06/01	Stamler, et al.				
	AI 6,291,424			09/18/01	Stamler, et al.				
FOREIGN				N PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL	ATION NO	
	AL	WO 96/16645	06-Jun-96	PCT					
	MA	WO 96/15797	30-May-96	PCT					
	AN	WO 96/17604	13-Jun-96	PCT		-			
	AO	WO 93/09806	27-May-93	PCT		·			
	AP	WO 93/12068	24-Jun-93	PCT	ļ 				
	AQ	EP 0604143	29-Jun-94	EPO					
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)			
	Stamler, J. et al., "S-Nitrosylation of Proteins with Nitric Oxide: Synthesis and Characterization of Biologically Active Compounds," Proc. Natl. Acad. Sci. USA, 89:444-448 (1992)								
	AS	_		nibition of Platelet Ac Coronary Angioplasty,"			44:145	8-	
	AT			eversible Binding of Ni a Bloodsucking Insect,				541	
EXAMIN	IER			DATE CONSIDERED					

PTO 1410 REPRODUCED			ATTORNEY DOCKET NO. 1818.1009-009	APPLICAT 10/045				
umi 1	INFO	MATION DISCLOSURE CI IN AN APPLICATION	TATION	APPLICANT Jonathan S. Stamler	, et al.			
MOA		October 29, 2002 several sheets if nece	ssary)	FILING DATE October 23, 2001	CONFIRMA 3692	TION NO.	GROUP 1651	
TRAD	END			PATENT DOCUMENTS				
EXAM- INER INI- TIAL		DOCUMENT NU	MBER	ISSUE DATE / PUBLICATION DATE		NAME		
						REC	CEIV	'ED
						NOV	1 9 2	002
		<u> </u>	FOREIG	N PATENT DOCUMENTS		דברט רבו	AITED 1/	enn/20
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSI YES	ロロロノとう
	AL2	WO 94/22499	13-Oct-94	PCT				
-	AM2	WO 94/22482	13-Oct-94	PCT				
	AN2	WO 94/22306	13-Oct-94	PCT				
	A02	WO 96/30006	03-Oct-96	PCT				
	AP2	WO 97/10265	20-Mar-97	PCT			:	
	AQ2	WO 98/34955	13-AUG-98	PCT				
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertin	ent Pages,	Etc.)		
*	AU	Olsen, S.B. et al. "Enhancement of Platelet Deposition by Cross-Linked Hemoglobin in a Rat Carotid Endarterectomy Model," Circulation, 93 (2):327-332 (1996)					:ed	
	AV		Bound Reser	In Vivo Transfer of Noir and Low Molecula (1994)				L
	AW		ntial Treat	uation of Extracorpo ment for Sickle Cell			of Red	i
	AX	Kosaka, H. et al., "ESR Spectral Transition by Arteriovenous Cycle in Nitric Oxide Hemoglobin of Cytokine-Treated Rats," Am. J. Physiol., 266(5):1400-1405 (1994)						
	AY			tural Effects in Alky . <i>Chem., 259(1):</i> 80-87		e Oxida	tion c)f
	AZ	Greenburg, A.G. and Kim, H.W., "Nitrosyl Hemoglobin Formation In-Vivo After Intravenous Administration of a Hemoglobin-Based Oxygen Carrier in Endotoxemic Rats," Artif. Cells, Blood Substitutes, Immobilization Biotechnol., 23(3):271-276 (1995)						
	AR2			aling: Nitrosylation de," <i>Cell, 78</i> :931-936		ed Tar	get	
EXAMI	NER	·		DATE CONSIDERED				

PTO-1440 REPRODUCED			ATTORNEY DOCKET NO. APPLICATION NO. 1818.1009-009 10/045,603							
, 1	INFOR	TATION DISCLOSURE CI IN AN APPLICATION	TATION	APPLICANT Jonathan S. Stamler, et al.						
HOY		Coctober 29, 2002 Several sheets if nece	essary)	FILING DATE October 23, 2001	CONFIRMA 3692	TION NO.	GROUP 1651	-		
IRAI		<u> </u>		PATENT DOCUMENTS						
EXAM- INER INI- TIAL		DOCUMENT NUI	MBER	ISSUE DATE / PUBLICATION DATE		REC	EIVE	D		
						NOV 1	9 200	2		
						CH CENT	ER 1600)/2900		
			FOREIG	N PATENT DOCUMENTS	, L	OH OEM				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSL YES	ATION ON		
•										
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinen	t Pages,	Etc.)				
	AS2	Nitrosothiols: 1 by S-Nitrosylat:	Implications ion and Acc	J.S., "NO ⁺ , NO ⁻ , and NO s for Regulation of Phy eleration of Disulfide (2): 279-285 (1995)	ysiologi	ical Fu	action	ıs of		
	AT2			ransport from Human Red 1995)	d Blood	Cells,	" Meth	ıods		
-	AU2			.S., "Donors of Nitrogonn Wiley & Sons Ltd. (es," Me	thods	In		
	AV2			, M., "Preparation and Nitric Oxide Research						
	AW2	Clancy, R.M. et al., "Nitric Oxide Reacts with Intracellular Glutathione and Activates the Hexose Monophosphate Shunt in Human Neutrophils: Evidence for S-Nitrosogluthathione as a Bioactive Intermediary," Proc. Natl. Acad. Sci. USA, 91:3680-3684 (1994)								
	AX2	Ignarro, L.J. et al., "Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates," The Jounal of Pharmacology and Experimental Therapeutics, 218(3):739-749								
	AY2	Simon, D.I. et al., "Effect of Nitric Oxide Synthase Inhibition on Bleeding Time in Humans," Journal of Cardiovascular Pharmacology, 26:339-342 (1995)								
	AZ2			yl Hemoglobin Producti mia In Rats," <i>Neurosci</i>						
EXAMI	AS2 Arnelle, D.R. and Stan Nitrosothiols: Implication and Biochem. and Biophys. AT2 Kondo, T. et al., "The in Enzymology, 252:72 AU2 Feelisch, M. and Stan Nitric Oxide Research AV2 Stamler, J.S. and Feel Nitrosothiols," Method Ltd. (1996) AW2 Clancy, R.M. et al., Glutathione and Active Neutrophils: Evidence Intermediary," Proc. AX2 Ignarro, L.J. et al., by Organic Nitrates, for the Involvement of Journal of Pharmacology (1981) AY2 Simon, D.I. et al., Bleeding Time in Human 26:339-342 (1995) AZ2 Kumura, E. et al., "Nafter Focal Cerebral			DATE CONSIDERED						

				,					
PTO-1449 REPRODUCED IN AN APPLICATION IN AN APPLICATION				ATTORNEY DOCKET NO. 1818.1009-009	APPLICATION 10/045				
				APPLICANT Jonathan S. Stamler,	et al.				
1142	2002 y	October 29, 2002 several sheets if nece	essary)	FILING DATE October 23, 2001	CONFIRMA 3692	ATION NO.	GROUP 1651		
BAOFMARK? U.S. PATENT DOCUMENTS									
EXAM- INER INI- TIAL		DOCUMENT NU	MBER	ISSUE DATE / PUBLICATION DATE		MRECEIVE			
						1	10V 1	9 2002	
						TECH	CENTER	R 1600	
			FOREIG	N PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSI YES	ATION ON	
•									
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertine	nt Pages,	Etc.)	<u></u>		
	AR3			haemoglobin: A Dynamic ol," <i>Nature, 380:</i> 221-		-	lood		
	AS3	Diriga, i. ce ar.	n Derivativ	n Paramagnetic Resonar es: I. Human Hemoglobi 969)			Nitric		
4	AT3	<u> </u>	•	ng of 21 Thiol Reagent Cells," Eur. J. Bioche			•		
•	AU3	Garel, M-C. et al., "Covalent Binding of Gluthathione to Hemoglobin: I. Inhibition of Hemoglobin S Polymerization," J. of Biol. Chem., 261(31): 14704-14709 (1986)							
	AV3	in Healthy Humar	n Whole Bloo	ndence of the Metaboli od on the Oxygenation acol., 106:507-508 (19	of Its F			NO)	
	AW3	Riubzyna, n. cc	Nitrogenou	Blood Cells Generate Nus Vasodilators," <i>Toxi</i>					
	AX3			ole of Thiols in the T " Biochem. 34:7177-718			Nitros	0	
	АҰЗ			od Flow Regulation by radient," Science, 276		_		in	
	AZ3) — '	•	osothiol Repletion by on," <i>PNAS, 98(10)</i> :5792					
	AR4	Pawloski, J.R. & Bioactivity," Na		port by Red Blood Cell 622-626 (2001).	s of Nit	ric Ox	ide		
EXAMI	NER			DATE CONSIDERED					
				L					